Your Health. Your Family. Your Choice.
Administered by: Unknown Purchased by: Unknown
Life Threatening? No
Write-up: Information has been received from the authors in published literature article. The aim of this study was to investigate HPV vaccinated women''s experiences with side effects caused by the HPV vaccine. Qualitative interviews were conducted with eight women, aged 25-44 years, who experienced side effects from vaccination against HPV. They were included in the study if aged 18 years or above and if they had received their HPV vaccination within the past three years. Adult women were chosen as a target group as they were believed to be more contemplative and reflective than young girls. This case concerns to a 25 year old female patient who was healthy before vaccination. The patient had no children. On an unknown date, the patient received the first dose of unidentified Merck HPV vaccine administered (name not provided) (lot number, expiration date, dose, route, frequency and indication were unknown) for prophylaxis, because she had fear of cancer and she trusted in her physician. The fear of cancer was based on the women''s own risk perception, which could be influenced by their family history of cancer. On an unknown date, the patient received the second dose of unidentified Merck HPV vaccine administered (name not provided) (lot number, expiration date, dose, route, frequency and indication were unknown) and on an unspecified date in 2012 she received the third dose of unidentified Merck HPV vaccine administered (name not provided) (lot number, expiration date, dose, route, frequency and indication were unknown). On unknown date, the patient experienced an unspecified side effect from the vaccination with unidentified Merck HPV vaccine (name not provided) the time of the side effects was after the first injection and aggravated after the next injection (on an unknown date). The authors considered the side effect was related to the vaccination with unidentified Merck HPV vaccine (name and lot number not provided). This is one of several cases received from the same literature article (1612DNK004981, 1612DNK004588, 1612DNK004996, 1612DNK004841, 1612DNK004850, 1612DNK004656, 1612DNK004576). Follow up information has been received via the author of the article on 19-JAN-2017. The patient received the vaccine, GARDASIL, on unknown dates in 2012. The adverse events (including migraine, sleeping problems, heart palpitations, bruises and hormonal changes) had an onset date in 2012. The outcome was reported as worsened. Seriousness criteria were reported as: "disability". Treatment for the adverse reactions was cannabis oil. Additional information is not expected as the reporter has no further information. Reporter, patient, product, event and narrative were updated. Sender''s Comments: DK-009507513-1612DNK004576: DK-009507513-1612DNK004588: DK-009507513-1612DNK004656: DK-009507513-1612DNK004841: DK-009507513-1612DNK004850: DK-009507513-1612DNK004981: DK-009507513-1612DNK004996.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166